Update on the treatment options for multiple sclerosis

Expert Review of Clinical Immunology

Volumn 6, Issue 1, 2010, Pages 77-88

  Niino, Masaaki ^a   Sasaki, Hidenao ^a  

^a HOKKAIDO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Glatiramer acetate; IFN ; Mitoxantrone; Monoclonal antibodies; Multiple sclerosis; Natalizumab; Pharmacogenetics; Therapy

Indexed keywords

4 AMINOPYRIDINE; ALEMTUZUMAB; ATORVASTATIN; AZATHIOPRINE; BETA INTERFERON; BETA1A INTERFERON; BG 00012; CLADRIBINE; CYCLOPHOSPHAMIDE; DACLIZUMAB; DOXYCYCLINE; FINGOLIMOD; FUMADERM; FUMARIC ACID; GLATIRAMER; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMMUNOGLOBULIN; INTERFERON BETA SERINE; LAQUINIMOD; METHOTREXATE; METHYLPREDNISOLONE; MEVINOLIN; MITOXANTRONE; NATALIZUMAB; NEUTRALIZING ANTIBODY; PIRFENIDONE; RILUZOLE; RITUXIMAB; SIMVASTATIN; TERIFLUNOMIDE; UNCLASSIFIED DRUG;

ASTHENIA; BRADYCARDIA; CARDIOTOXICITY; CLINICAL TRIAL; DRUG DOSE COMPARISON; DRUG EFFECT; DRUG EFFICACY; DRUG INDICATION; DRUG MEGADOSE; DRUG METABOLISM; DRUG SAFETY; DYSPNEA; FEVER; HEADACHE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HERPES SIMPLEX; HUMAN; IDIOPATHIC THROMBOCYTOPENIC PURPURA; INFECTION; INJECTION SITE REACTION; LEUKEMIA; LEUKOCYTE COUNT; LOW DRUG DOSE; LYMPHOCYTOPENIA; MULTIPLE SCLEROSIS; NAUSEA; PHARMACOGENETICS; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; RETINA MACULA EDEMA; REVIEW; RHINOPHARYNGITIS; RISK BENEFIT ANALYSIS; SIDE EFFECT; SKIN CANCER;

ANTIBODIES, MONOCLONAL; DRUG THERAPY, COMBINATION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MULTIPLE SCLEROSIS; PATIENT SELECTION; RISK ASSESSMENT; TREATMENT OUTCOME;

EID: 77649115036     PISSN: 1744666X     EISSN: None     Source Type: Journal    
DOI: 10.1586/eci.09.75     Document Type: Review

References (92)

1. The IFNB Multiple Sclerosis Study Group. Interferon b-1b is effective in relapsingremitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 43(4), 655-661 (1993).
2. Johnson KP, Brooks BR, Cohen JA et al. Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a Phase III multicenter, double-blind placebocontrolled trial. Neurology 45(7), 1268-1276 (1995).
3. Jacobs LD, Cookfair DL, Rudick RA et al.; The Multiple Sclerosis Collaborative Research Group (MSCRG). Intramuscular interferon b-1a for disease progression in relapsing multiple sclerosis. Ann. Neurol. 39(3), 285-294 (1996).
4. The Prevention of Relapses and Disability by Interferon b-1a Subcutaneously in Multiple Sclerosis (PRISMS) Study Group. Randomised double-blind placebocontrolled study of interferon b-1a in relapsing/remitting multiple sclerosis. Lancet 352(9139), 1498-1504 (1998).
5. Jacobs LD, Beck RW, Simon JH et al. Intramuscular interferon b-1a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS Study Group. N. Engl. J. Med. 343(13), 898-904 (2000).
6. Comi G, Filippi M, Barkhof F et al. Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised study. Lancet 357(9268), 1576-1582 (2001).
7. Kappos L, Polman CH, Freedman MS et al. Treatment with interferon b-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes. Neurology 67(7), 1242-1249 (2006).
8. Kappos L, Freedman MS, Polman CH et al. Effect of early versus delayed interferon b-1b treatment on disability after a first clinical event suggestive of multiple sclerosis: a 3-year follow-up analysis of the BENEFIT study. Lancet 370(9585), 389-397 (2007).
9. Comi G. PreCISe Study. Presented at: 60th Annual Meeting of the American Academy of Neurology. Chicago, IL, USA, 12-19 April 2008.
10. Kinkel RP, Kollman C, O'Connor P et al. IM interferon b-1a delays definite multiple sclerosis 5 years after a first demyelinating event. Neurology 66(5), 678-684 (2006).
11. European Study Group on Interferon b-1b in Secondary Progressive MS. Placebo-controlled multicentre randomised trial of interferon b-1b in treatment of secondary progressive multiple sclerosis. Lancet 352(9139), 1491-1497 (1998).
12. Panitch H, Miller A, Paty D, Weinshenker B; North American Study Group on Interferon b-1b in Secondary Progressive MS. Interferon b-1b in secondary progressive MS: results from a 3-year controlled study. Neurology 63(10), 1788-1795 (2004).
13. Kappos L, Weinshenker B, Pozzilli C et al. Interferon b-1b in secondary progressive MS: a combined analysis of the two trials. Neurology 63(10), 1779-1787 (2004).
14. Panitch H, Goodin DS, Francis G et al. Randomized, comparative study of interferon b-1a treatment regimens in MS: The EVIDENCE Trial. Neurology 59(10), 1496-1506 (2002).
15. Panitch H, Goodin D, Francis G et al. Benefits of high-dose, high-frequency interferon b-1a in relapsing-remitting multiple sclerosis are sustained to 16 months: final comparative results of the EVIDENCE trial. J. Neurol. Sci. 239(1), 67-74 (2005).
16. Durelli L, Verdun E, Barbero P et al. Every-other-day interferon b-1b versus once-weekly interferon b-1a for multiple sclerosis: results of a 2-year prospective randomised multicentre study (INCOMIN). Lancet 359(9316), 1453-1460 (2002).
17. Koch-Henriksen N, Sørensen PS, Christensen T et al. A randomized study of two interferon-b treatments in relapsingremitting multiple sclerosis. Neurology 66(7), 1056-1060 (2006).
18. Flechter S, Vardi J, Pollak L, Rabey JM. Comparison of glatiramer acetate (Copaxone) and interferon b-1b (Bferon) in multiple sclerosis patients: an open-label 2-year follow-up. J. Neurol. Sci. 197(1-2), 51-55 (2002).
19. Cadavid D, Wolansky LJ, Skurnick J et al. Efficacy of treatment of MS with IFNb-1b or glatiramer acetate by monthly brain MRI in the BECOME study. Neurology 72(23), 1976-1983 (2009).
20. O'Connor P, Arnason B, Comi G et al. Interferon b-1b 500 mcg, interferon b-1b 250 mcg and glatiramer acetate: primary outcomes of the Bferon® /Bseron® Efficacy Yielding Outcomes of a New Dose Study. Presented at: 60th Annual Meeting of the American Academy of Neurology. Chicago, IL, USA, 12-19 April 2008.
21. Mikol DD, Barkhof F, Chang P et al. Comparison of subcutaneous interferon b-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the REbif vs Glatiramer Acetate in Relapsing MS Disease [REGARD] study): a multicentre, randomised, parallel, open-label trial. Lancet Neurol. 7(10), 903-914 (2008).
22. Duddy M, Niino M, Adatia F et al. Distinct effector cytokine profiles of memory and naive human B cell subsets and implication in multiple sclerosis. J. Immunol. 178(10), 6092-6099 (2007).
23. Hartung HP, Gonsette R, König N et al. Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, doubleblind, randomised, multicentre trial. Lancet 360(9350), 2018-2025 (2002).
24. Gonsette RE. Compared benefit of approved and experimental immunosuppressive therapeutic approaches in multiple sclerosis. Expert. Opin Pharmacother. 8(8), 1103-1116 (2007).
25. Chan A, Stüve O, von Ahsen N. Immunosuppression in clinical practice: approaches to individualized therapy. J. Neurol. 255(Suppl. 6), 22-27 (2008).
26. Vollmer T, Panitch H, Bar-Or A et al. Glatiramer acetate after induction therapy with mitoxantrone in relapsing multiple sclerosis. Mult. Scler. 14(5), 663-670 (2008).
27. Arnold DL, Campagnolo D, Panitch H et al. Glatiramer acetate after mitoxantrone induction improves MRI markers of lesion volume and permanent tissue injury in MS. J. Neurol. 255(10), 1473-1478 (2008).
28. Edan G, Edan G, Comi G et al. The French-Italian Mitoxantrone- Interferon-b trial: a 3-year randomized study. Mult. Scler. 13(Suppl. 2), S22-S23 (2007).
29. Rommer PS, Stüve O, Goertsches R, Mix E, Zettl UK. Monoclonal antibodies in the therapy of multiple sclerosis: an overview. J. Neurol. 255(Suppl. 6), 28-35 (2008).
30. Lutterotti A, Martin R. Getting specific: monoclonal antibodies in multiple sclerosis. Lancet Neurol. 7(6), 538-547 (2008).
31. Niino M, Bodner C, Simard ML et al. Natalizumab effects on immune cell responses in multiple sclerosis. Ann. Neurol. 59(5), 748-754 (2006).
32. Stüve O, Marra CM, Jerome KR et al. Immune surveillance in multiple sclerosis patients treated with natalizumab. Ann. Neurol. 59(5), 743-747 (2006).
33. Stüve O, Cravens PD, Frohman EM et al. Immunologic, clinical, and radiologic status 14 months after cessation of natalizumab therapy. Neurology 72(5), 396-401 (2009).
34. Miller DH, Khan OA, Sheremata WA et al. A controlled trial of natalizumab for relapsing multiple sclerosis. N. Engl. J. Med. 348(1), 15-23 (2003).
35. Polman CH, O'Connor PW, Havrdova E et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N. Engl. J. Med. 354(9), 899-910 (2006).
36. Rudick RA, Stuart WH, Calabresi PA et al. Natalizumab plus interferon b-1a for relapsing multiple sclerosis. N. Engl. J. Med. 354(9), 911-923 (2006).
37. Goodman AD, Rossman H, Bar-Or A et al. GLANCE: results of a Phase 2, randomized, double-blind, placebocontrolled study. Neurology 72(9), 806-812 (2009).
38. Kleinschmidt-DeMasters BK, Tyler KL. Progressive multifocal leukoencephalopathy complicating treatment with natalizumab and interferon b-1a for multiple sclerosis. N. Engl. J. Med. 353(4), 369-374 (2005).
39. Langer-Gould A, Atlas SW, Green AJ, Bollen AW, Pelletier D. Progressive multifocal leukoencephalopathy in a patient treated with natalizumab. N. Engl. J. Med. 353(4), 375-381 (2005).
40. Van Assche G, Van Ranst M, Sciot R et al. Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn's disease. N. Engl. J. Med. 353(4), 362-368 (2005).
41. Goodin DS, Cohen BA, O'Connor P, Kappos L, Stevens JC; Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Assessment: the use of natalizumab (Tysabri) for the treatment of multiple sclerosis (an evidence-based review): report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology 71(10), 766-773 (2008).
42. Wenning W, Haghikia A, Laubenberger J et al. Treatment of PML unfolding during monotherapy with natalizumab. Presented at: 1st World Congress on Treatment and Research in Multiple Sclerosis. Montreal, QC, Canada, 17-20 September 2008.
43. Stüve O, Marra CM, Cravens PD et al. Potential risk of progressive multifocal leukoencephalopathy with natalizumab therapy: possible interventions. Arch. Neurol. 64(2), 169-176 (2007).
44. Khatri BO, Man S, Giovannoni G et al. Effect of plasma exchange in accelerating natalizumab clearance and restoring leukocyte function. Neurology 72(5), 402-409 (2009).
45. Hauser SL, Waubant E, Arnold DL et al. B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. N. Engl. J. Med. 358(7), 676-688 (2008).
46. Hawker KS, O'Connor P, Freedman MS et al. Efficacy and safety of rituximab in patients with primary progressive multiple sclerosis: results of a randomized, double-blind, placebo-controlled, multicenter trial. Presented at: 1st World Congress on Treatment and Research in Multiple Sclerosis. Montreal, QC, Canada, 17-20 September 2008.
47. Molloy ES, Calabrese LH. Progressive multifocal leukoencephalopathy in patients with rheumatic diseases: are patients with systemic lupus erythematosus at particular risk? Autoimmun. Rev. 8(2), 144-146 (2008).
48. Freim Wahl SG, Folvik MR, Torp SH. Progressive multifocal leukoencephalopathy in a lymphoma patient with complete remission after treatment with cytostatics and rituximab: case report and review of the literature. Clin. Neuropathol. 26(2), 68-73 (2007).
49. Pelosini M, Focosi D, Rita F et al. Progressive multifocal leukoencephalopathy: report of three cases in HIV-negative hematological patients and review of literature. Ann. Hematol. 87(5), 405-412 (2008).
50. Cox AL, Thompson SA, Jones JL et al. Lymphocyte homeostasis following therapeutic lymphocyte depletion in multiple sclerosis. Eur. J. Immunol. 35(11), 3332-3342 (2005).
51. Coles AJ, Compston DA, Selmaj KW et al.; CAMMS223 Trial Investigators. Alemtuzumab vs. interferon b-1a in early multiple sclerosis. N. Engl. J. Med. 359(17), 1786 - 1801 (2008).
52. Bielekova B, Richert N, Howard T et al. Humanized anti-CD25 (daclizumab) inhibits disease activity in multiple sclerosis patients failing to respond to interferon b. Proc. Natl Acad. Sci. USA 101(23), 8705-8708 (2004).
53. Rose JW, Watt HE, White AT, Carlson NG. Treatment of multiple sclerosis with an anti-interleukin-2 receptor monoclonal antibody. Ann. Neurol. 56(6), 864-867 (2004).
54. Rose JW, Burns JB, Bjorklund J, Klein J, Watt HE, Carlson NG. Daclizumab Phase II trial in relapsing and remitting multiple sclerosis: MRI and clinical results. Neurology 69(8), 785-789 (2007).
55. Bielekova B, Howard T, Packer AN et al. Effect of anti-CD25 antibody daclizumab in the inhibition of inflammation and stabilization of disease progression in multiple sclerosis. Arch. Neurol. 66(4), 483-489 (2009).
56. Montalban X, Wynn D, Kaufmann M, Wang M, Fong A. Preliminary CHOICE results: a Phase 2, randomised, placebocontrolled multicentre study of subcutaneous daclizumab in patients with active, relapsing forms of multiple sclerosis on interferon b. Presented at: 23rd Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS). Prague, Czech Republic, 11-14 October 2007.
57. Kappos L, Antel J, Comi G et al. Oral fingolimod (FTY720) for relapsing multiple sclerosis. N. Engl. J. Med. 355(11), 1124-1140 (2006).
58. O'Connor P, Comi G, Montalban X et al. Oral fingolimod (FTY720) in multiple sclerosis: two-year results of a Phase II extension study. Neurology 72(1), 73-79 (2009).
59. Cohen J, Pelletier J, Kappos L et al. Oral fingolimod (FTY720) versus interferon b-1a in relapsing-remitting multiple sclerosis: results from a Phase III study (TRANSFORMS). Presented at: 61st Annual Meeting of the American Academy of Neurology. Seattle, WA, USA, 25 April-2 May 2009.
60. Aktas O, Waiczies S, Smorodchenko A et al. Treatment of relapsing paralysis in experimental encephalomyelitis by targeting Th1 cells through atorvastatin. J. Exp. Med. 197(6), 725-733 (2003).
61. Floris S, Blezer EL, Schreibelt G et al. Blood-brain barrier permeability and monocyte infiltration in experimental allergic encephalomyelitis: a quantitative MRI study. Brain 127(3), 616-627 (2004).
62. Paintlia AS, Paintlia MK, Singh AK et al. Regulation of gene expression associated with acute experimental autoimmune encephalomyelitis by lovastatin. J. Neurosci. Res. 77(1), 63-81 (2004).
63. Paintlia AS, Paintlia MK, Khan M, Vollmer T, Singh AK, Singh I. HMG-CoA reductase inhibitor augments survival and differentiation of oligodendrocyte progenitors in animal model of multiple sclerosis. FASEB J. 19(11), 1407-1421 (2005).
64. Vollmer T, Key L, Durkalski V et al. Oral simvastatin treatment in relapsingremitting multiple sclerosis. Lancet 363(9421), 1607-1608 (2004). (Pubitemid 38625664)
65. Birnbaum G, Cree B, Altafullah I, Zinser M, Reder AT. Combining b interferon and atorvastatin may increase disease activity in multiple sclerosis. Neurology 71(18), 1390-1395 (2008).
66. Paul F, Waiczies S, Wuerfel J et al. Oral high-dose atorvastatin treatment in relapsing-remitting multiple sclerosis. PLoS ONE 3(4), e1928 (2008).
67. Beutler E, Sipe JC, Romine JS, Koziol JA, McMillan R, Zyroff J. The treatment of chronic progressive multiple sclerosis with cladribine. Proc. Natl Acad. Sci. USA 93(4), 1716-1720 (1996). (Pubitemid 26075191)
68. Sipe JC, Romine JS, Koziol JA, McMillan R, Zyroff J, Beutler E. Cladribine in treatment of chronic progressive multiple sclerosis. Lancet 344(8914), 9-13 (1994).
69. Romine JS, Sipe JC, Koziol JA, Zyroff J, Beutler E. A double-blind, placebocontrolled, randomized trial of cladribine in relapsing-remitting multiple sclerosis. Proc. Assoc. Am. Physicians. 111(1), 35-44 (1999).
70. Sipe JC, Romine JS, Koziol J, Zyroff J, McMillan R, Beutler E. Cladribine improves relapsing-remitting MS: a double blind placebo controlled study. Neurology 48, A340 (1997).
71. Stelmasiak Z, Solski J, Nowicki J, Jakubowska B, Ryba M, Grieb P. Effect of parenteral cladribine on relapse rates in patients with relapsing forms of multiple sclerosis: results of a 2-year, double-blind, placebo-controlled, crossover study. Mult. Scler. 15(6), 767-770 (2009).
72. Giovannoni G. Results from the CLARITY Study: a Phase III, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of Oral Cladribine in Relapsing-Remitting Multiple Sclerosis (RRMS). Presented at: 61st Annual Meeting of the American Academy of Neurology. Seattle, WA, USA, 25 April-2 May 2009.
73. Yang JS, Xu LY, Xiao BG, Hedlund G, Link H. Laquinimod (ABR-215062) suppresses the development of experimental autoimmune encephalomyelitis, modulates the Th1/Th2 balance and induces the Th3 cytokine TGF-b in Lewis rats. J. Neuroimmunol. 156(1-2), 3-9 (2004).
74. Polman C, Barkhof F, Sandberg-Wollheim M et al. Treatment with laquinimod reduces development of active MRI lesions in relapsing MS. Neurology 64(6), 987-991 (2005).
75. Comi G, Pulizzi A, Rovaris M et al. Effect of laquinimod on MRI-monitored disease activity in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebocontrolled Phase IIb study. Lancet 371(9630), 2085-2092 (2008).
76. Ockenfels HM, Schultewolter T, Ockenfels G, Funk R, Goos M. The antipsoriatic agent dimethylfumarate immunomodulates T-cell cytokine secretion and inhibits cytokines of the psoriatic cytokine network. Br. J. Dermatol. 139(3), 390-395 (1998).
77. Schimrigk S, Brune N, Hellwig K et al. Oral fumaric acid esters for the treatment of active multiple sclerosis: an open-label, baseline-controlled pilot study. Eur. J. Neurol. 13(6), 604-610 (2006).
78. Kappos L, Gold R, Miller DH et al. Efficacy and safety of oral fumarate in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled Phase IIb study. Lancet 372(9648), 1463-1472 (2008).
79. O'Connor PW, Li D, Freedman MS et al. A Phase II study of the safety and efficacy of teriflunomide in multiple sclerosis with relapses. Neurology 66(6), 894-900 (2006).
80. Mancardi G, Saccardi R. Autologous haematopoietic stem-cell transplantation in multiple sclerosis. Lancet Neurol. 7(7), 626-636 (2008).
81. Rudick RA, Polman CH. Current approaches to the identification and management of breakthrough disease in patients with multiple sclerosis. Lancet Neurol. 8(6), 545-559 (2009).
82. Costello F, Stüve O, Weber MS, Zamvil SS, Frohman E. Combination therapies for multiple sclerosis: scientific rationale, clinical trials, and clinical practice. Curr. Opin. Neurol. 20(3), 281-285 (2007).
83. Minagar A, Alexander JS, Schwendimann RN et al. Combination therapy with interferon b-1a and doxycycline in multiple sclerosis: an open-label trial. Arch. Neurol. 65(2), 199-204 (2008).
84. Jeffery DR. Use of combination therapy with immunomodulators and immunosuppressants in treating multiple sclerosis. Neurology 63(Suppl. 6), S41-S46 (2004).
85. Tullman MJ, Lublin FD. Combination therapy in multiple sclerosis. Curr. Neurol. Neurosci. Rep. 5(3), 245-248 (2005).
86. Smith DR, Weinstock-Guttman B, Cohen JA et al. A randomized blinded trial of combination therapy with cyclophosphamide in patients-with active multiple sclerosis on interferon b. Mult. Scler. 11(5), 573-582 (2005).
87. Cohen JA, Imrey PB, Calabresi PA et al. Results of the Avonex Combination Trial (ACT) in relapsing-remitting MS. Neurology 72(6), 535-541 (2009).
88. Goodman AD, Brown TR, Krupp LB et al. Sustained-release oral fampridine in multiple sclerosis: a randomised, doubleblind, controlled trial. Lancet 373(9665), 732-738 (2009).
89. Río J, Tintoré M, Nos C, Téllez N, Galán I, Montalban X. Interferon b in relapsingremitting multiple sclerosis. An eight years experience in a specialist multiple sclerosis centre. J. Neurol. 252(7), 795-800 (2005).
90. Goodin DS, Frohman EM, Hurwitz B et al. Neutralizing antibodies to interferon b: assessment of their clinical and radiographic impact: an evidence report: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology 68(13), 977-984 (2007). (Pubitemid 46569129)
91. Leary SM, Thompson AJ. Primary progressive multiple sclerosis: current and future treatment options. CNS Drugs 19(5), 369-376 (2005).
92. Wilinsky JS, Narayana PA, O'Connor P et al. Glatiramer acetate in primary progressive multiple sclerosis: results of a multinational, multicenter, double-blind, placebo-controlled trial. Ann. Neurol. 61(1), 14-24 (2007).